E-Mail A Monash University study has uncovered for the first time a way to prevent and reverse damage caused by broken-heart syndrome, also known as Takotsubo cardiomyopathy. Using mouse models, the pre-clinical study published in the acclaimed journal Signal Transduction and Targeted Therapy, has shown the cardioprotective benefit of a drug called Suberanilohydroxamic acid, or SAHA, dramatically improved cardiac health and reversed the broken-heart. The landmark study used SAHA to target genes and is a world first for Takotsubo cardiomyopathy. SAHA, currently used for cancer treatment, is approved by the US Food and Drug Administration (FDA) and Australian Therapeutic Goods Administration (TGA), works by providing a protective benefit to genes and in particular the acetylation/deacetylation (Ac/Dc) index, an important process that regulates gene expression.